Viscosupplementation Market Size & Growth Forecast 2027–2036, By Segments (End-use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Viscosupplementation Market size was over USD 6.2 billion in 2026 and is likely to grow at a 5.89% CAGR between 2027 and 2036, exceeding USD 10.99 billion by 2036. The industry revenue for 2027 is assessed at USD 6.51 billion.

• Base Year Value (2026): USD 6.2 billion
• CAGR (2027-2036): 5.89%
• Forecast Year Value (2036): USD 10.99 billion
• Historical Data Period: 2022-2026
• Largest Region: Asia Pacific
• Forecast Period: 2027-2036

Viscosupplementation Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Asia Pacific accounted for 48.55% of the market in 2026, supported by a large patient pool, sustained osteoarthritis treatment volumes, and expanding healthcare access across major economies.
  • Europe is expected to expand at an 11.07% CAGR as aging populations, established musculoskeletal care pathways, and wider adoption of injection-based therapies increase demand for non-surgical osteoarthritis management.

• Segment Momentum:

  • Orthopedic Clinics/ASCs held a 61.17% share in 2026 because they efficiently manage evaluation, injection procedures, and follow-up care within specialized outpatient settings, supporting streamlined treatment pathways.
  • Single Injection led with a 46.05% share and the strongest growth due to its one-visit treatment approach. Reduced appointment requirements and greater convenience make it highly attractive to both providers and patients.

• Market Expansion Drivers:

  • Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies.
  • Preference for minimally invasive single-injection treatments expanding outpatient adoption.
  • Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies.

• Leading Market Participants:

  Key companies in the viscosupplementation market include DePuy Synthes (United States), Fidia Farmaceutici S.p.A. (Italy), Sanofi S.A. (France), Smith & Nephew plc (United Kingdom), Anika Therapeutics, Inc. (United States), Seikagaku Corporation (Japan), Zimmer Biomet Holdings, Inc. (United States), Ferring Pharmaceuticals B.V. (Switzerland), Lifecore Biomedical, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 6.2 billion
  • 2027 Estimated Market Size: USD 6.51 billion.
  • Projected Market Size: USD 10.99 billion by 2036
  • Growth Forecasts: 5.89% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: Asia Pacific
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Orthopedic Clinics/ASCs (End-use) | Single Injection (Product)
  • Emerging Opportunity Segment: Orthopedic Clinics/ASCs (End-use) | Single Injection (Product)

Market Growth Drivers and Industry Trends

Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies

An expanding aging population and the increasing prevalence of osteoarthritis are supporting the viscosupplementation market by creating greater demand for therapies aimed at managing joint pain and improving mobility. Osteoarthritis commonly affects weight-bearing joints and can limit daily activities as symptoms progress, increasing the need for treatment options that can be incorporated into patient care. Viscosupplementation provides an established therapeutic approach for joint-related symptoms, supporting its use among patients seeking non-surgical management of osteoarthritis-associated discomfort.

Preference for minimally invasive single-injection treatments expanding outpatient adoption

Growing preference for convenient and minimally invasive care is strengthening the viscosupplementation market, particularly as patients and healthcare providers seek treatment approaches that can be administered without surgical intervention. Single-injection formulations can reduce the number of treatment visits compared with multi-injection regimens, making therapy more convenient within outpatient settings. Their administration within routine clinical environments can also simplify treatment scheduling while supporting patient acceptance of joint pain management options that require limited procedural intervention.

Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies

Broader reimbursement availability can improve access to viscosupplementation by reducing financial barriers for eligible patients and supporting treatment consideration within routine clinical care. At the same time, early-stage clinical adoption of viscosupplementation therapies can encourage healthcare providers to incorporate these options into treatment pathways for appropriate patients with joint pain. Greater familiarity among clinicians and patients, together with improved coverage conditions, can facilitate wider utilization across outpatient and orthopedic care settings.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies	2.40%	High	Asia Pacific, Europe, North America	High	Near Term
Preference for minimally invasive single-injection treatments expanding outpatient adoption	2.10%	High	North America, Europe	Medium	Near Term
Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies	1.70%	Moderate	Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

Asia Pacific (Largest Region) vs Europe (Fastest-Growing Region)

Asia Pacific held the largest share of the viscosupplementation market, representing 48.55% in 2026. The region’s leading position is supported by a growing aging population, rising prevalence of osteoarthritis, and increasing awareness of non-surgical approaches for managing joint pain. Improving healthcare infrastructure and expanding access to orthopedic care are supporting greater adoption of viscosupplementation procedures. In addition, growing healthcare expenditure and improving availability of minimally invasive treatment options are strengthening demand across major regional healthcare markets.

Europe is the fastest-growing region, driven by increasing demand for minimally invasive osteoarthritis treatments and greater attention to preserving mobility among aging populations. Improvements in healthcare access and growing physician familiarity with injectable therapies are supporting wider use of viscosupplementation. The region’s emphasis on patient-centered care, rehabilitation, and alternatives to more invasive orthopedic interventions is also contributing to market development, while continued improvements in clinical practice are encouraging adoption across healthcare systems.

Key Country Insights

United States

Orthopedic Treatment Expansion

The viscosupplementation market in the U.S. is supported by rising use in osteoarthritis management across orthopedic and sports medicine clinics. Providers in the U.S. are emphasizing minimally invasive joint therapies alongside outpatient treatment models and expanding patient access through specialty care networks.

Japan

Aging Population Care

Japan’s viscosupplementation demand is influenced by a rapidly aging population and increasing prevalence of knee osteoarthritis. Clinicians in Japan focus on joint preservation therapies that delay surgical intervention and support mobility maintenance in elderly patients.

South Korea

Aesthetic Orthopedic Clinics

South Korea integrates viscosupplementation into private orthopedic and sports medicine clinics offering advanced joint care services. Providers in South Korea are expanding non-surgical treatment options to meet growing demand from active and aging populations.

Germany

Conservative Clinical Adoption

Germany shows cautious adoption of viscosupplementation therapies, with usage concentrated in orthopedic specialists and private clinics. German healthcare providers prioritize evidence-based treatment protocols and cost-effectiveness in managing degenerative joint conditions.

France

Reimbursed Therapy Pathways

France supports viscosupplementation usage through structured clinical pathways within orthopedic care systems. Healthcare providers in France focus on regulated administration and patient selection criteria aligned with national treatment guidelines for osteoarthritis.

Italy

Specialist Orthopedic Use

Italy’s viscosupplementation market is concentrated in orthopedic specialist settings addressing knee and joint degeneration cases. Italian clinicians emphasize conservative treatment approaches that support pain management and functional improvement before surgical consideration.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Orthopedic Clinics/ASCs (Largest & Fastest-Growing Segment)

Orthopedic Clinics/ASCs dominated the viscosupplementation market and represented the fastest-growing end-use segment, accounting for a 61.17% share in 2026. Their strong position is supported by the growing use of minimally invasive orthopedic interventions and the suitability of outpatient settings for viscosupplementation procedures. These facilities can provide focused musculoskeletal care with efficient treatment workflows, supporting convenient patient access and timely administration. Increasing preference for specialized orthopedic services and streamlined procedural environments continues to reinforce demand within this end-use segment.

Product Segment Analysis: Single Injection (Largest & Fastest-Growing Segment)

The single injection segment held the leading position in the viscosupplementation market and was also the fastest-growing product segment, representing a 46.05% share in 2026. Its adoption is supported by the convenience of completing treatment through a single administration, which can simplify scheduling and improve patient adherence compared with regimens requiring multiple visits. Healthcare providers can also benefit from more efficient treatment delivery and reduced procedural burden, while patients may favor approaches that minimize repeated clinical appointments. These advantages are strengthening the role of single-injection products across viscosupplementation treatment settings.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Hospitals, Orthopedic Clinics/ASCs	Orthopedic Clinics/ASCs	Orthopedic Clinics/ASCs
Product	Single Injection, Three Injection, Five Injection	Single Injection	Single Injection

Competitive Landscape and Market Positioning

Key companies in the viscosupplementation market:

1. DePuy Synthes (United States)

2. Fidia Farmaceutici S.p.A. (Italy)

3. Sanofi S.A. (France)

4. Smith & Nephew plc (United Kingdom)

5. Anika Therapeutics Inc. (United States)

6. Seikagaku Corporation (Japan)

7. Zimmer Biomet Holdings Inc. (United States)

8. Ferring Pharmaceuticals B.V. (Switzerland)

9. Lifecore Biomedical Inc. (United States)

10. F. Hoffmann-La Roche Ltd (Switzerland)

The viscosupplementation market is evolving through continuous efforts to improve treatment durability, injection efficiency, and patient comfort in joint care therapies. Participants are prioritizing the development of advanced formulations with enhanced viscosity profiles and longer-lasting therapeutic benefits. Strategic collaborations supporting clinical research and innovation are also contributing to the expansion of next-generation viscosupplementation solutions across orthopedic applications.

Industry Development/News

Company Name	Date	Key Development
Cipla	Dec-25	Cipla launched Ciplostem, a DCGI-approved cell therapy for knee osteoarthritis in India, in partnership with Stempeutics Research. This launch signifies the company’s strategic entry into orthobiologic medicine, providing a long-term, regenerative therapeutic alternative to traditional hyaluronic acid-based viscosupplementation for patients suffering from degenerative knee osteoarthritis.
Anika Therapeutics	Mar-25	Anika Therapeutics finalized the divestiture of Parcus Medical to Medacta Group. This strategic portfolio optimization allows Anika to concentrate its resources and capital on its core hyaluronic acid-based pain management solutions, strengthening its competitive focus within the viscosupplementation and regenerative medicine segments.
IBSA Group	Feb-24	IBSA UK launched the SINOVIAL range for osteoarthritis treatment. Utilizing proprietary NAHYCO technology, the product combines high and low molecular weight hyaluronic acid to enhance joint lubrication. This expansion underscores IBSA’s commitment to advancing HA-based therapeutic formulations to address the evolving clinical needs of osteoarthritis patients in the UK.
Zimmer Biomet	Jan-24	Zimmer Biomet launched VISCO-3, a three-injection high molecular weight hyaluronate treatment for moderate-stage knee osteoarthritis. Clinical data demonstrated a 52% reduction in patient pain at 12 weeks with relief lasting up to six months, reinforcing the company’s position in the global market for intermediate-term osteoarthritis pain management.
Bioventus	Oct-24	Bioventus divested its Advanced Rehabilitation segment to Accelmed Partners for USD 45 million. This divestiture reflects a broader strategic realignment, allowing the company to streamline operations and focus its investment capacity on its core musculoskeletal and orthobiologic product lines, including its flagship HA-based viscosupplementation offerings.
Fidia Farmaceutici	Sep-24	The U.S. FDA approved Hymovis for the treatment of knee osteoarthritis in patients who have failed to respond to first-line therapy. The approval, based on clinical non-inferiority to Hyalgan, introduces a new, high-viscosity cross-linked hyaluronic acid option to the U.S. market, expanding the competitive landscape for intra-articular injections.
Juniper Biologics	Apr-22	Juniper Biologics and Kolon Life Science entered a licensing agreement to develop and commercialize TissueGene-C, an investigational cell-mediated gene therapy for knee osteoarthritis. This partnership represents a strategic move toward incorporating advanced biological alternatives into the standard of care for joint degeneration, potentially disrupting traditional viscosupplementation treatment pathways.
Avanos Medical	Dec-21	Avanos Medical acquired OrthogenRx to expand its chronic pain management portfolio. The acquisition granted Avanos access to established viscosupplementation therapies for knee osteoarthritis pain, providing the company with an immediate footprint in the OA market and enhancing its ability to offer comprehensive, non-surgical solutions to pain management specialists.
Seikagaku Corporation	Aug-21	Seikagaku Corporation launched Hylink, a single-injection cross-linked hyaluronate hydrogel, in the Taiwan market. Developed in partnership with TCM Biotech, this advanced viscosupplement is designed to improve the viscoelasticity of the synovial fluid, providing long-lasting symptomatic relief for knee osteoarthritis patients and enhancing Seikagaku’s presence in the Asian orthopedic market.